|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 96 - week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1 -infected adults : ASSERT study 显示文摘 | Moyle GJ Stellbrink HJ Compston J | 2013 | Antivir Ther2013，18，： | 1 |
| 2 | Current knowledge of HIV-1 reverse transcriptase mutations selected during nucleoside analogue therapy- the potential to use resistance data to guide clinical decisions 显示文摘 | Moyle GJ | 1997 | J Antimicrob Chemother1997，40，6： | 1 |
| 3 | Epidemiology and pre- dictivefactors for ehemokinereceptor use in HIV-1 infection显示文摘 | Moyle GJ Wildfire A Mandalia S | 2005 | J Infect Dis2005，191，6： | 1 |
| 4 | Hyperlactataemia and lactic acidosis during antiretroviral therapy: reproducibility and possible risk factors显示文摘 | Moyle GJ Datta D Mandalia S | 2002 | AIDS2002，16，10： | 1 |
| 5 | Abacavir once or twice daily combined with once-daily lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults: Results of the ziagen once daily in antiretroviral combination study显示文摘 | Moyle GJ Dejesus E Cahn P | 2005 | J Acquir Immune Defic Syndr2005，38，4： | 1 |
| 6 | Boosted PIS:competition hots up显示文摘 | Moyle GJ | 2003 | AIDS Read2003，13，9： | 1 |
| 7 | Peripheral neuropathy with nucleoside antiretrovirals : risk factors, incidence and management 显示文摘 | Moyle GJ Sadler M | 1998 | Drug Saf1998，19，6： | 1 |
| 8 | Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study显示文摘 | Post FA Moyle GJ Stellbrink HJ | 2010 | J Acquir Immune Defic Syndr2010，55，1： | 1 |
| 9 | Dietary advice with orwithout prevastatin for the management of hypercholesteroiaemiaassociated with protease inhibitor therapy 显示文摘 | Moyle GJ Lloyd M Reynolds B | 2001 | AIDS2001，15，13： | 1 |
| 10 | A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analog in persons with lipoatrophy显示文摘 | Moyle GJ Sabin CA Cartledge J | 2006 | AIDS2006，20，16： | 1 |
| 11 | Randomized comparison of renal effects,efficacy,and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine,administered with efavirenz,in antiretroviral-naive,HIV-1-infected adults:48-week results from the ASSERT study显示文摘 | Post FA Moyle GJ Stellbrink HJ | 2010 | J Acquir Immune Defic Syndr2010，55，1： | 1 |
| 12 | Current knowledge of HIV-1 reverse transcriptase mutations selected during nucleoside analogue therapy: the potential to use resistance data to guide clinical decisions显示文摘 | Moyle GJ | 1997 | J Antimicrob Chemother1997，40，： | 1 |
| 13 | A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy显示文摘 | Moyle GJ Sabin CA Cartledge J | 2006 | AIDS2006，20，16： | 1 |
| 14 | A randomized comparative trial of continued abacavir/lamivudine plus efavirenz or replacement with efavirenz/emtricitabine/tenofovir DF in hypercholesterolemic HIV - 1 infected individuals 显示文摘 | Moyle GJ Orkin C Fisher M | 2015 | PLoS One2015，10，01： | 1 |
| 15 | Abacavir once or twice daily combined with once- daily lamivudine and efavirenz for the treatment of antiretroviral - naive HIV - infected adults:results of the ziagen once daily in antiretroviral combination Study显示文摘 | Moyle GJ DeJesus E Cahn P | 2005 | J Acquir Immune Defic Syndr2005，38，4： | 1 |
| 16 | A randomized open-label study of immediate versus delayed polylactie acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection显示文摘 | Moyle GJ Lysakova L Brown S | 2004 | HIV Med2004，5，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员